Hardman & Co Q&A with Dr Martin Hall: Alliance Pharma plc (LON:APH)
12th November 2018
Hardman and Co’s Dr Martin Hall discusses Alliance Pharma plc in this exclusive interview with DirectorsTalk
Hardman and Co’s Dr Martin Hall discusses Alliance Pharma plc in this exclusive interview with DirectorsTalk
Alliance Pharma Plc (LON:APH) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall joins DirectorsTalk. Martin explains how he believes the company has now grown into
Alliance Pharma (LON:APH) is a profitable, cash-generative, specialty pharma business. The proportion of sales generated from higher margin international star brands is rising rapidly, and will be boosted by the
Alliance Pharma Plc (LON:APH) is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company
Alliance Pharma Plc (LON:APH) buy-and-build strategy is to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and wound care products from Sinclair
Alliance Pharma Plc (LON:APH) buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma
Alliance Pharma plc (LON:APH) buy-and-build strategy which is to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from
Alliance Pharma Plc (LON:APH) has adopted a buy-and-build strategy to evolve through a series of 28 acquisitions into a profitable, cash generative, specialty pharma business. The acquisition of part of
Alliance Pharma Plc (LON:APH) has developed through a series of 28 acquisitions as part of a buy and build strategy, culminating in the most recent £127.5m acquisition of 27 primarily
By Keith Hiscock, CEO. The Office for National Statistics has just published its bi-annual report ‘Ownership of quoted shares for UK domiciled companies’ using 2014 data. For the first time,
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
